AbilityPharma's Fight Against Cancer
March 13, 2024, 1:37 pm
Location: Spain, Catalonia, Cerdanyola del Vallès
Employees: 11-50
Founded date: 2009
Total raised: $12.01M
AbilityPharma, a Barcelona-based biopharmaceutical company, secured a hefty EUR 7 million in funding to fuel its battle against cancer. The round, led by a European-Canadian syndicate of life sciences investors, aims to support the company's phase 2b clinical study of ABTL0812, a promising antitumor compound for pancreatic cancer patients.
Carles Domènech, the CEO of AbilityPharma, expressed gratitude for the support from investors like CTI Life Sciences Fund, Inveready, and the EIC Fund. Their backing will propel the development of ABTL0812, bringing hope to those fighting pancreatic cancer.
The company's mission is clear: to revolutionize cancer treatment by addressing unmet medical needs. With ABTL0812 undergoing Phase 2b trials, AbilityPharma is on the frontline of innovation in the fight against this deadly disease.
As the battle rages on, AbilityPharma's dedication to improving cancer care shines bright. With each milestone reached, the company moves closer to providing a beacon of hope for patients in need.
Carles Domènech, the CEO of AbilityPharma, expressed gratitude for the support from investors like CTI Life Sciences Fund, Inveready, and the EIC Fund. Their backing will propel the development of ABTL0812, bringing hope to those fighting pancreatic cancer.
The company's mission is clear: to revolutionize cancer treatment by addressing unmet medical needs. With ABTL0812 undergoing Phase 2b trials, AbilityPharma is on the frontline of innovation in the fight against this deadly disease.
As the battle rages on, AbilityPharma's dedication to improving cancer care shines bright. With each milestone reached, the company moves closer to providing a beacon of hope for patients in need.